NATALIE BLANCHARD: Open Payments
NPI 1558846568 · LEWISTON, ME. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,330 in 28 payments from 9 companies in 2025. Trend: 2023 $1,118 · 2024 $831 · 2025 $1,330
Food & beverage: $1,330
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 9 | $321 |
| Janssen Biotech, Inc. | 2 | $237 |
| ABBVIE INC. | 6 | $183 |
| Boston Scientific Corporation | 2 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $157 |
| Gilead Sciences, Inc. | 1 | $94 |
| GENZYME CORPORATION | 1 | $81 |
| Ardelyx, Inc. | 2 | $58 |
| Intercept Pharmaceuticals, Inc. | 1 | $30 |
Products named: REZDIFFRA, TREMFYA, ENTYVIO, Livdelzi, EXALT Model D, DUPIXENT, General - Biliary Devices, LINZESS.
Industry payments across ME — which companies pay providers there.
